

If you are presented with a TRAVATAN® Ophthalmic Solution 0.004% prescription or refill, please notify customers of this change and contact their Eye Care Professional to determine if TRAVATAN Z® Solution is an appropriate alternative*

TRAVATAN Z® Solution compares to TRAVATAN® Solution as follows¹⁻³:

	TRAVATAN® Solution	TRAVATAN Z® Solution
Bottle Size	2.5 mL, 5 mL	Same
Managed Care Coverage	Primarily preferred access (Tier 2)	Same
NDC Number	2.5 mL 0065 0266 25 5 mL 0065 0266 34	2.5 mL 0065 0260 25 5 mL 0065 0260 05
Patent Expiration	December 2014	Same

Remember the 

IMPORTANT SAFETY INFORMATION:

TRAVATAN® and TRAVATAN Z® Solutions are indicated for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension whom are intolerant of other IOP-lowering medications or insufficiently responsive (failed to achieve target IOP determined after multiple measurements over time) to another IOP-lowering medication. TRAVATAN® and TRAVATAN Z® Solutions are contraindicated in patients with known hypersensitivity to travoprost or any other ingredients in this product.

Prostaglandin analogues including travoprost ophthalmic solution 0.004% have been reported to cause changes to pigmented tissues. The most frequently reported changes have been increased pigmentation of the iris and periorbital tissue (eyelid) and increased pigmentation and growth of eyelashes. These changes may be permanent.

TRAVATAN® and TRAVATAN Z® Solutions may gradually change eye color, increasing the amount of brown pigmentation in the iris by increasing the number of melanosomes (pigment granules) in melanocytes. The long-term effects on the melanocytes and the consequences of potential injury to the melanocytes and/or deposition of pigment granules to other areas of the eye are currently unknown.

The most common adverse event observed in studies with TRAVATAN® Solution and TRAVATAN Z® Solution was ocular hyperemia which was reported in 30% to 50% of patients. Ocular events reported at an incidence of 5% to 10% included decreased visual acuity, eye discomfort, foreign body sensation, pain and pruritus. The recommended dosage is one drop in the affected eye(s) once daily in the evening.

Before prescribing TRAVATAN Z® Ophthalmic Solution, please read the full prescribing information.

References:

1. TRAVATAN Z® Solution package insert. Ft. Worth, TX: Alcon; 2006.
2. TRAVATAN® Solution package insert. Ft. Worth, TX: Alcon; 2004.
3. www.FingertipFormulary.com. Medicare Prescription Drug Plan. Accessed April 21, 2010.

*Eye Care Professionals have also been notified of this change by Alcon Laboratories

**TRAVATAN® Ophthalmic Solution 0.004%
is being discontinued in the US**

**TRAVATAN Z® Solution is the BAK-free
formulation of travoprost
and is still available in the US**



TRAVATAN Z® Solution compares to TRAVATAN® Solution as follows^{1,2}:

	TRAVATAN® Solution	TRAVATAN Z® Solution
Dosing	QD	Same
Active Ingredient	travoprost 0.004%	Same
Preservative	benzalkonium chloride	sofZia™ Preservative System

Remember the Z®

IMPORTANT SAFETY INFORMATION:

TRAVATAN® and TRAVATAN Z® Solutions are indicated for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension whom are intolerant of other IOP-lowering medications or insufficiently responsive (failed to achieve target IOP determined after multiple measurements over time) to another IOP-lowering medication. TRAVATAN® and TRAVATAN Z® Solutions are contraindicated in patients with known hypersensitivity to travoprost or any other ingredients in this product.

Prostaglandin analogues including travoprost ophthalmic solution 0.004% have been reported to cause changes to pigmented tissues. The most frequently reported changes have been increased pigmentation of the iris and periorbital tissue (eyelid) and increased pigmentation and growth of eyelashes. These changes may be permanent.

TRAVATAN® and TRAVATAN Z® Solutions may gradually change eye color, increasing the amount of brown pigmentation in the iris by increasing the number of melanosomes (pigment granules) in melanocytes. The long-term effects on the melanocytes and the consequences of potential injury to the melanocytes and/or deposition of pigment granules to other areas of the eye are currently unknown.

The most common adverse event observed in studies with TRAVATAN® Solution and TRAVATAN Z® Solution was ocular hyperemia which was reported in 30% to 50% of patients. Ocular events reported at an incidence of 5% to 10% included decreased visual acuity, eye discomfort, foreign body sensation, pain and pruritus. The recommended dosage is one drop in the affected eye(s) once daily in the evening.

Before prescribing TRAVATAN Z® Ophthalmic Solution, please read the full prescribing information.